AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3070936 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-poor platelet concentrates (lp-PC) stored at 22 degrees C for 3 days
Number of subjects: 31
Study 3070936 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-poor platelet concentrates (lp-PC) stored at 22 degrees C for 5 days
Number of subjects: 31
Study 3070936 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-poor platelet concentrates (lp-PC) regardless of storage duration
Number of subjects: 31
Study 31797039 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent treatment (2 times weekly for 5 weeks)
Number of subjects: 0
Study 31797039 — intervention group
Group type: COMPARATOR
Intervention: Consecutive treatment (5 times weekly for 2 weeks)
Number of subjects: 0
Study 31797039 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Intermittent and Consecutive)
Number of subjects: 0
Study 30409184 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 g of fructose (supplied in a 2‐L volume of 10% fructose in water) daily for 2 weeks
Number of subjects: 33
Study 28079600 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (4×2.5 mg/kg)
Number of subjects: 30
Study 28079600 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 30
Study 26333205 — intervention group
Group type: EXPERIMENTAL
Intervention: Insert pads with stretch pants
Number of subjects: 78
Study 26333205 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-piece all-in-one diapers
Number of subjects: 78
Study 26333205 — intervention group
Group type: EXPERIMENTAL
Intervention: Pull-up pants
Number of subjects: 78
Study 26333205 — intervention group
Group type: EXPERIMENTAL
Intervention: Belted/T-shape diapers
Number of subjects: 78
Study 26333205 — intervention group
Group type: EXPERIMENTAL
Intervention: Researcher observations (Method 1)
Number of subjects: 78
Study 26333205 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare assistants logging (Method 2)
Number of subjects: 78
Study 23739499 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrum Memory (intervention)
Number of subjects: 0
Study 23739499 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 21978382 — intervention group
Group type: EXPERIMENTAL
Intervention: GJS (water extract granules, 3 g/pack, 3 times a day) with Duolac7S (powder form, 1 capsule, 2 times a day)
Number of subjects: 60
Study 18287807 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary IL-18 levels measured 24 hours after coronary angiography
Number of subjects: 150
Study 18287807 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary NGAL levels measured 24 hours after coronary angiography
Number of subjects: 150
Study 18287807 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-18 as a predictive marker for AKI onset
Number of subjects: 150
Study 18287807 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-18 and NGAL performance in early diagnosis of CIN
Number of subjects: 150
Study 18287807 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-18 as a predictive marker for later major cardiac events
Number of subjects: 150
Study 17341047 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) for FBSS and CRPS Type I
Number of subjects: 0
Study 17341047 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) for refractory angina pectoris
Number of subjects: 0
Study 17341047 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) for peripheral vascular disease (PVD)
Number of subjects: 0
Study 12957733 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon mitral valvuloplasty (BMV)
Number of subjects: 16
Study 12957733 — intervention group
Group type: COMPARATOR
Intervention: Control (no valvuloplasty)
Number of subjects: 16
Study 11132586 — intervention group
Group type: EXPERIMENTAL
Intervention: Light pressure effleurage (leg rubbing) during genetic amniocentesis
Number of subjects: 200
Study 11132586 — intervention group
Group type: COMPARATOR
Intervention: No effleurage (control group) during genetic amniocentesis
Number of subjects: 200
Study 11132586 — intervention group
Group type: EXPERIMENTAL
Intervention: Light pressure effleurage (leg rubbing)
Number of subjects: 200
Study 8836914 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN)‐alpha therapy
Number of subjects: 21
Study 8836914 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 21
Study 1562097 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Number of subjects: 40
Study 1562097 — intervention group
Group type: COMPARATOR
Intervention: Tramadol
Number of subjects: 40
Study 3933677 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin acetate 0.3 microgram/kg
Number of subjects: 15
Study 3933677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30712752 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI)
Number of subjects: 0
Study 30712752 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation-based intervention
Number of subjects: 0
Study 28317503 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (maximum dosage 200 mg/day) with brief counseling
Number of subjects: 129
Study 28317503 — intervention group
Group type: COMPARATOR
Intervention: Placebo with brief counseling
Number of subjects: 129
Study 26084250 — intervention group
Group type: EXPERIMENTAL
Intervention: Preincisional infiltration with bupivacaine and epinephrine (study group, 27 patients)
Number of subjects: 47
Study 26084250 — intervention group
Group type: COMPARATOR
Intervention: No preincisional infiltration (control group, 20 patients)
Number of subjects: 47
Study 24739538 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mg azilsartan
Number of subjects: 309
Study 24739538 — intervention group
Group type: COMPARATOR
Intervention: 8-mg candesartan cilexetil
Number of subjects: 309
Study 21551316 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous albinterferon alfa-2b (albIFN) doses (900-1800 µg once every 2 or 4 weeks) administered for either 24 weeks (HCV genotypes 2/3) or 48 weeks (genotype 1), plus daily oral ribavirin
Number of subjects: 0
Study 21551316 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous albinterferon alfa-2b (albIFN) doses (900-1800 µg once every 2 or 4 weeks)
Number of subjects: 0
Study 19588303 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day
Number of subjects: 37
Study 19588303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 17879830 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ligation of the anterior branch of the internal iliac artery (group I)
Number of subjects: 28
Study 17879830 — intervention group
Group type: COMPARATOR
Intervention: Ligation 2 cm proximal to bifurcation (group II)
Number of subjects: 28
Study 14694241 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 100 microg/day for 1 week
Number of subjects: 21
Study 14694241 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg/day for 1 week
Number of subjects: 21
Study 14694241 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 1600 microg/day for 1 week
Number of subjects: 21
Study 14694241 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 100 microg/day for 2 weeks
Number of subjects: 21
Study 14694241 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg/day for 2 weeks
Number of subjects: 21
Study 14694241 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 1600 microg/day for 2 weeks
Number of subjects: 21
Study 14694241 — intervention group
Group type: COMPARATOR
Intervention: Non-sequential regimen of Budesonide 1600 microg/day for 2 weeks
Number of subjects: 21
Study 14694241 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (various doses)
Number of subjects: 21
Study 12021703 — intervention group
Group type: EXPERIMENTAL
Intervention: Polestriding exercise
Number of subjects: 52
Study 12021703 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise control
Number of subjects: 52
Study 10825858 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Tartar Control with Baking Soda & Peroxide Fluoride Toothpaste
Number of subjects: 180
Study 10825858 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquafresh Advanced Whitening Toothpaste with Fluoride
Number of subjects: 180
Study 10825858 — intervention group
Group type: COMPARATOR
Intervention: Crest Regular Fluoride Toothpaste
Number of subjects: 180
Study 10825858 — intervention group
Group type: EXPERIMENTAL
Intervention: Rembrandt Tartar Control Low Abrasion Fluoride Whitening Toothpaste
Number of subjects: 180
Study 7548909 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination at 1 month
Number of subjects: 66
Study 7548909 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination at 2 months
Number of subjects: 66
Study 7548909 — intervention group
Group type: COMPARATOR
Intervention: Control group (not vaccinated)
Number of subjects: 66
Study 2245968 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant‐DNA human growth hormone treatment
Number of subjects: 24
Study 2245968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 6999640 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicitropeptide (BCP-Compound)
Number of subjects: 55
Study 6999640 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (Tagamet)
Number of subjects: 55
Study 6596425 — intervention group
Group type: EXPERIMENTAL
Intervention: Protect dentifrice
Number of subjects: 0
Study 6596425 — intervention group
Group type: EXPERIMENTAL
Intervention: Protect with fluoride dentifrice
Number of subjects: 0
Study 6596425 — intervention group
Group type: COMPARATOR
Intervention: Sensodyne dentifrice
Number of subjects: 0
Study 29080386 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (600 mg/day)
Number of subjects: 19
Study 29080386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 27869287 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 42
Study 27869287 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (FNT)
Number of subjects: 42
Study 23760989 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation
Number of subjects: 14
Study 23760989 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 14
Study 23174471 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 61
Study 23174471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 20970087 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent sexual health intervention with trained health workers providing youth-friendly health services.
Number of subjects: 20
Study 18759613 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive Neurostimulation (RNS) system
Number of subjects: 7
Study 15492354 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayley Scales of Infant Development at 1 year
Number of subjects: 135
Study 15492354 — intervention group
Group type: EXPERIMENTAL
Intervention: Fagan Test of Infant Intelligence at 1 year
Number of subjects: 135
Study 15492354 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year test scores
Number of subjects: 135
Study 15492354 — intervention group
Group type: EXPERIMENTAL
Intervention: Low scores at 8 years (< or =85)
Number of subjects: 135
Study 11181380 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH27899 (Ziracin) 1 mg/kg
Number of subjects: 0
Study 11181380 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH27899 (Ziracin) 3 mg/kg
Number of subjects: 0
Study 11181380 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH27899 (Ziracin) 6 mg/kg
Number of subjects: 0
Study 11181380 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH27899 (Ziracin) 9 mg/kg
Number of subjects: 0
Study 11181380 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated doses of SCH27899
Number of subjects: 0
Study 11181380 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 0
Study 9441084 — intervention group
Group type: EXPERIMENTAL
Intervention: Neopterin levels in serum
Number of subjects: 21
Study 9441084 — intervention group
Group type: EXPERIMENTAL
Intervention: Neopterin release from culture supernatants of MNC
Number of subjects: 21
Study 9441084 — intervention group
Group type: COMPARATOR
Intervention: Neopterin release from MNC stimulated with PPD
Number of subjects: 21
Study 9441084 — intervention group
Group type: COMPARATOR
Intervention: Stimulation index (SI) in lymphocyte proliferation assay
Number of subjects: 21
Study 9441084 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum concentration of neopterin
Number of subjects: 21
Study 8148683 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed rest (49 of 100 patients)
Number of subjects: 103
Study 8148683 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 103
Study 3069879 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocarboxazid treatment
Number of subjects: 18
Study 3069879 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (control)
Number of subjects: 18
Study 30657100 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate and chondroitin sulfate capsules (GS/CS)
Number of subjects: 100
Study 30657100 — intervention group
Group type: COMPARATOR
Intervention: Cosamin DS® (glucosamine hydrochloride and chondroitin sulfate)
Number of subjects: 100
Study 30657100 — intervention group
Group type: EXPERIMENTAL
Intervention: Both GS/CS and Cosamin DS®
Number of subjects: 100
Study 27434393 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucroferric oxyhydroxide (SFOH) 1.0-3.0 g/day
Number of subjects: 1059
Study 27434393 — intervention group
Group type: COMPARATOR
Intervention: Sevelamer carbonate (SEV) 2.4-14.4 g/day
Number of subjects: 1059
Study 27434393 — intervention group
Group type: COMPARATOR
Intervention: Both SFOH and SEV
Number of subjects: 1059
Study 24750568 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-AMP cream
Number of subjects: 107
Study 24750568 — intervention group
Group type: COMPARATOR
Intervention: Control group (emollient cream)
Number of subjects: 107
Study 22994864 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with health insurance
Number of subjects: 4079
Study 22994864 — intervention group
Group type: COMPARATOR
Intervention: Participants without health insurance
Number of subjects: 4079
Study 20067907 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17689627 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper IUD
Number of subjects: 599
Study 17689627 — intervention group
Group type: COMPARATOR
Intervention: Hormonal contraception
Number of subjects: 599
Study 15609029 — intervention group
Group type: EXPERIMENTAL
Intervention: LHTLc (20 consecutive nights of hypoxia)
Number of subjects: 33
Study 15609029 — intervention group
Group type: EXPERIMENTAL
Intervention: LHTLi (20 nights of intermittent hypoxia)
Number of subjects: 33
Study 15609029 — intervention group
Group type: COMPARATOR
Intervention: CON (control group)
Number of subjects: 33
Study 15609029 — intervention group
Group type: EXPERIMENTAL
Intervention: LHTLc and LHTLi (pooled data)
Number of subjects: 33
Study 12472205 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat-plate hemofilters
Number of subjects: 31
Study 12472205 — intervention group
Group type: COMPARATOR
Intervention: Hollow-fiber hemofilters
Number of subjects: 31
Study 12472205 — intervention group
Group type: EXPERIMENTAL
Intervention: Single heparin administration site
Number of subjects: 31
Study 12472205 — intervention group
Group type: COMPARATOR
Intervention: Double site heparin administration
Number of subjects: 31
Study 12472205 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 m2 hemofilters (Filtral 8)
Number of subjects: 31
Study 12472205 — intervention group
Group type: COMPARATOR
Intervention: 1.30 m2 hemofilters (Filtral 12)
Number of subjects: 31
Study 9650737 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (beta-adrenoceptor antagonist)
Number of subjects: 0
Study 9650737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8077800 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g of phosphocreatine in 200 ml of solvent for 10 days (Group 1)
Number of subjects: 37
Study 8077800 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl in the same scheme (Group 2)
Number of subjects: 37
Study 2916427 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular (LV) electrode positive
Number of subjects: 21
Study 2916427 — intervention group
Group type: COMPARATOR
Intervention: Left ventricular (LV) electrode negative
Number of subjects: 21
Study 2916427 — intervention group
Group type: COMPARATOR
Intervention: Both configurations
Number of subjects: 21
Study 180393 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly 5‐fluorouracil, intravenously
Number of subjects: 60
Study 180393 — intervention group
Group type: COMPARATOR
Intervention: Daily physiologic doses of conjugated estrogens by mouth
Number of subjects: 60
Study 180393 — intervention group
Group type: COMPARATOR
Intervention: Weekly 5‐fluorouracil, intravenously + placebo
Number of subjects: 60
Study 31934946 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17β‐estradiol (n=30)
Number of subjects: 95
Study 31934946 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen (n=29)
Number of subjects: 95
Study 31934946 — intervention group
Group type: COMPARATOR
Intervention: Placebo pills and patch (n=36)
Number of subjects: 95
Study 30286007 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-enhanced visual learning (CEVL) module
Number of subjects: 0
Study 30286007 — intervention group
Group type: COMPARATOR
Intervention: Control group (no access to CEVL)
Number of subjects: 0
Study 28302931 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 119
Study 28302931 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 119
Study 26694694 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (twice weekly for six months)
Number of subjects: 42
Study 26694694 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 42
Study 25263601 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection of botulinum toxin type A
Number of subjects: 30
Study 25263601 — intervention group
Group type: COMPARATOR
Intervention: Manual needle placement injection of botulinum toxin type A
Number of subjects: 30
Study 21875222 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative affect (NA) mood induction and exposure to NA cues (NA images and NA music)
Number of subjects: 32
Study 21875222 — intervention group
Group type: COMPARATOR
Intervention: Neutral images and neutral music (control group)
Number of subjects: 32
Study 19459087 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-hypnosis (HYP)
Number of subjects: 37
Study 19459087 — intervention group
Group type: COMPARATOR
Intervention: EMG biofeedback relaxation (BIO)
Number of subjects: 37
Study 17092978 — intervention group
Group type: COMPARATOR
Intervention: Diphenhydramine (75 mg)
Number of subjects: 16
Study 17092978 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 16
Study 15158296 — intervention group
Group type: EXPERIMENTAL
Intervention: sc‐FOS (10.6g/day)
Number of subjects: 30
Study 15158296 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrine plus aspartame 15 g/day)
Number of subjects: 30
Study 11642081 — intervention group
Group type: EXPERIMENTAL
Intervention: lipantil therapy for 3 months
Number of subjects: 40
Study 11642081 — intervention group
Group type: COMPARATOR
Intervention: healthy males (control group)
Number of subjects: 40
Study 10439887 — intervention group
Group type: EXPERIMENTAL
Intervention: Manidipine 10 mg
Number of subjects: 54
Study 10439887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 7606298 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured discussions, information, and mailed reminders
Number of subjects: 0
Study 7606298 — intervention group
Group type: COMPARATOR
Intervention: Control group (no structured discussions, information, or reminders)
Number of subjects: 0
Study 2192972 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-927 (2%); single drop administered
Number of subjects: 33
Study 2192972 — intervention group
Group type: COMPARATOR
Intervention: Pilocarpine (1% q.d.); single dose administered
Number of subjects: 33
Study 2192972 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-927 (2%); single dose administered
Number of subjects: 33
Study 2192972 — intervention group
Group type: COMPARATOR
Intervention: Pilocarpine (1%); single dose administered
Number of subjects: 33
Study 856702 — intervention group
Group type: EXPERIMENTAL
Intervention: Dequalinium chloride lozenges
Number of subjects: 44
Study 856702 — intervention group
Group type: COMPARATOR
Intervention: Void lozenges (Control)
Number of subjects: 44
Study 31884945 — intervention group
Group type: EXPERIMENTAL
Intervention: FamPALcare intervention (5-weekly sessions delivered by community-based nurses)
Number of subjects: 72
Study 31884945 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 72
Study 28782187 — intervention group
Group type: EXPERIMENTAL
Intervention: B-Vitamin therapy
Number of subjects: 56
Study 28782187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 25840480 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nails (IMN)
Number of subjects: 60
Study 25840480 — intervention group
Group type: COMPARATOR
Intervention: Volar locking plates (VLP)
Number of subjects: 60
Study 23393104 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 (1.0 mEq/kg per day)
Number of subjects: 71
Study 23393104 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruits and vegetables (dosed to reduce dietary acid by half)
Number of subjects: 71
Study 23393104 — intervention group
Group type: COMPARATOR
Intervention: Comparison between NaHCO3 and fruits and vegetables
Number of subjects: 71
Study 20554148 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive group program
Number of subjects: 753
Study 20554148 — intervention group
Group type: COMPARATOR
Intervention: Lecture-based information-only programs
Number of subjects: 753
Study 19169898 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin with parenteral nutrition
Number of subjects: 200